VEXAS Syndrome for the laboratory physician: a case report
By
Chaoying Chen
Miaomiao Chen
Tieqiao Chen
Yong Chen
Lingzhi Liu
Yixi Zhu
Xiaoming Yi
Shuguang He
May 6, 2026
Clinical Scorecard: VEXAS Syndrome: Insights for Laboratory Physicians from a Case Study
At a Glance
Category Detail
Condition VEXAS Syndrome Key Mechanisms Somatic mutations in the UBA1 gene leading to autoinflammatory features and hematological disorders. Target Population Patients with systemic inflammatory conditions and hematological irregularities. Care Setting Multidisciplinary clinical practice, including laboratory and hospital settings.
Key Highlights
VEXAS syndrome is characterized by fever, rash, arthritis, and hematological irregularities. Diagnosis involves identifying specific UBA1 gene mutations. Current treatments include corticosteroids, immunomodulatory agents, and AHSCT. Patients have an elevated risk of malignant neoplasms compared to other autoinflammatory diseases. Early diagnosis and management are crucial for improving patient outcomes. Guideline-Based Recommendations
Diagnosis
Utilize laboratory findings and genetic testing to confirm UBA1 mutations. Management
Administer high doses of corticosteroids and consider AHSCT for severe cases. Monitoring & Follow-up
Regularly assess inflammatory markers and hematological parameters. Risks
Monitor for the development of malignant neoplasms and other complications. Patient & Prescribing Data
Individuals with VEXAS syndrome and related systemic inflammatory conditions.
Corticosteroids and immunomodulatory therapies are primary treatment modalities.
Clinical Best Practices
Enhance awareness of VEXAS syndrome among laboratory physicians. Facilitate early identification and diagnosis through improved laboratory protocols. Collaborate within multidisciplinary teams for comprehensive patient management. Related Resources & Content
